Logos Global Management’s Vaxcyte PCVX Stock Holding History

Logos Global Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300,000	Closed	-$17.4M	–	84
2026 Q1	$17.4M	Sell	300,000 -350,000	-54%	-$19M	0.87%	37
2025 Q4	$30M	Buy	650,000 +25,000	+4%	+$1.12M	1.81%	19
2025 Q3	$22.5M	Buy	+625,000	New	+$20.7M	2.02%	22
2025 Q1	–	Sell	-300,000	Closed	-$24.6M	–	52
2024 Q4	$24.6M	Hold	300,000	–	–	2.87%	13
2024 Q3	$34.3M	Buy	+300,000	New	+$27M	3.7%	7
2021 Q1	–	Sell	-140,000	Closed	-$3.72M	–	68
2020 Q4	$3.72M	Buy	+140,000	New	+$5.2M	0.32%	42
2020 Q3	–	Sell	-455,000	Closed	-$14.4M	–	56
2020 Q2	$14.4M	Buy	+455,000	New	+$14.6M	2.87%	16

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Logos Global Management's PCVX Position: Q2 2026 in Review

Logos Global Management sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 300,000 shares — an estimated $17.4M sold.

Logos Global Management first reported a position in PCVX in Q2 2020 and held it in 7 quarters. The position peaked at $34.3M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Logos Global Management reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
Logos Global Management sold 300,000 Vaxcyte shares in Q2 2026, an estimated $17.4M.
Logos Global Management first reported a position in Vaxcyte in Q2 2020 and held it in 7 quarters.
Logos Global Management's Vaxcyte position peaked at $34.3M in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.